Exploring Nonantibiotic Adjuncts: Synergistic Effects of Esmolol and Carvedilol With Tigecycline
Canadian Journal of Infectious Diseases and Medical Microbiology · 2026-01 · 2026 (1)
DOI: 10.1155/cjid/1402388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Infectious Diseases and Medical Microbiology, online erschienen am 10.04.2026. Verfasst von Mehmet Erinmez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Medical Microbiology, Gaziantep University, Gaziantep, Türkiye, gantep.edu.tr. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Antimicrobial resistance poses a major global health threat, and carbapenem‐resistant Gram‐negative bacteria such as Klebsiella pneumoniae and Acinetobacter baumannii have been classified as critical priority pathogens. Although tigecycline provides coverage against multidrug resistant organisms, its use is limited by pharmacokinetic constraints and the emergence of resistance. This study investigates the in vitro synergistic potential of tigecycline combined with two β‐blockers, carvedilol and esmolol, against clinical isolates of K. pneumoniae , Proteus mirabilis , and A. baumannii .
Methods
Synergy was assessed using the disc diffusion, broth microdilution, and checkerboard methods. A total of 36 clinical isolates were tested. Esmolol and carvedilol were supplemented with tigecycline discs, and inhibition zone diameters were compared. Minimum inhibitory concentrations (MICs) and fractional inhibitory concentration indices (FICi) were calculated according to standard protocols.
Results
Both β‐blockers significantly enhanced tigecycline’s antibacterial activity across all isolates, as evidenced by increased inhibition zones and synergistic FICi values (≤ 0.5). Neither carvedilol nor esmolol exhibited intrinsic antimicrobial activity at therapeutic concentrations, suggesting their synergistic role is not based on direct bactericidal effects. These findings support the hypothesis that β‐blockers modulate bacterial susceptibility, possibly by interfering with quorum sensing or membrane dynamics.
Conclusion
Carvedilol and esmolol significantly potentiate tigecycline’s efficacy against MDR Gram‐negative pathogens in vitro. These results support repurposing β‐blockers as nonantibiotic adjuvants in antimicrobial therapy. Further molecular studies and in vivo validation are warranted to explore their potential in clinical applications and to better understand the mechanisms underlying the observed synergy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Medical Microbiology, Gaziantep University, Gaziantep, Türkiye, gantep.edu.tr.
- Department of Medical Microbiology, SANKO University Faculty of Medicine, Gaziantep, Türkiye.
ORCID-Profile: Mehmet Erinmez, İpek Koçer, Yasemin Zer
Zitieren
APA
Erinmez, M., Koçer, İ., & Zer, Y. (2026). Exploring Nonantibiotic Adjuncts: Synergistic Effects of Esmolol and Carvedilol With Tigecycline. Canadian Journal of Infectious Diseases and Medical Microbiology, 2026(1). https://doi.org/10.1155/cjid/1402388
Vancouver
Erinmez M, Koçer İ, Zer Y. Exploring Nonantibiotic Adjuncts: Synergistic Effects of Esmolol and Carvedilol With Tigecycline. Canadian Journal of Infectious Diseases and Medical Microbiology. 2026;2026(1). doi:10.1155/cjid/1402388
BibTeX
@article{Erinmez2026,
author = {Erinmez, Mehmet and Koçer, İpek and Zer, Yasemin},
title = {Exploring Nonantibiotic Adjuncts: Synergistic Effects of Esmolol and Carvedilol With Tigecycline},
journal = {Canadian Journal of Infectious Diseases and Medical Microbiology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/cjid/1402388}
}
EUVIMED